Histide™ has announced on December 2th, 2015 a publication in Nature Materials revealing mechanisms governing stem cell differentiation.
Histide™ is a biotech intellectual property platform company pioneering a new class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules™ (CRMs). This innovative platform builds on Histide’s expertise in the mechanisms underlying the cell’s microenvironmental sensing and signal transduction processes. The CRMs promote and stimulate the cell’s natural capacities to redirect its own fate by integrating accurate extracellular signals. This is at the heart of Histide’s groundbreaking approach of addressing diseases called Recoding Therapeutics™, that goes beyond traditional cell, gene or RNA based therapies. Histide has a technological breakthrough with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.
PhD Economics, Stanford University. He is Co-owner and CEO of an investment fund (Parter Capital Group, Germany).
PhD in Multidisciplinary Sciences, Co-inventor of Histide’s Patents. He is currently the CEO of Histide.
PhD in Multidisciplinary Sciences, Co-inventor of Histide’s Patents. She is currently the CSO of Histide.
Expert in the international Medical Device Business development.
PhD from Oxford University and European Patent Attorney. He is currently the Legal and IP Counsel of Histide.
Owner and Chairman of several companies and expert in stock-exchange transactions.
Renowned Swiss Medical Doctor and Professor (Fribourg Hospital) in the field of Orthopedics.
Expert in the Pharma Business Development, biotech deals and management regulations.
obtained a Ph.D. in stem cell biology and regenerative medicine from the University of Bordeaux (France) in 2011. He began his career by performing scientific research in the fields of Drug Design and Bioinformatics. He has then worked for more than 5 years on unraveling the mechanisms underlying the extracellular reprogramming of stem cells through the rational design of complex microenvironments. He has initiated and supervised several industry-academic collaboration projects. His expertise is in formulation development, from early stage conception and lab scale prototypes to clinical trial compositions. He is responsible for the leadership of Histide providing the operational and the scientific oversight to enable the company to meet its objectives.
obtained a Ph.D. in biophysics from the University of Montpellier (France) and Berkley University (US) in 2012. She began her career by performing scientific research in the fields of cancer and stem cell biology. She then worked for more than 5 years on unraveling the mechanisms of gene regulation by applying singlemolecule superresolution technologies to the study of mRNA transcription termination. Veronika has extensive experience in studying healthy and diseased cell biology. She conducts all of Histide’s research and development projects and new CRMs applications, manages all academic collaborations and is responsible for the scientific communication.
obtained a Ph.D. in chemical biology from the University of Oxford (Hertford College, UK) in 2006. He officially began his career in intellectual property in private practice in London in 2007 during which he passed his part-qualifying UK Patent Attorney exams. Ben then worked in Paris for one of the most renowned IP firm in Europe (Cabinet Beau de Loménie) where he fully qualified as a French and European Patent Attorney and handled hundreds of patent prosecution and contentious matters for important pharmaceutical companies. Ben has extensive experience dealing with all patent-related matters and is responsible of patent drafting, prosecution, valuation, litigation, IP strategy, and has been instrumental for Histide’s IP platform.
holds more than 30 years of experience in Administration, Finance and Strategy leadership positions. Mrs Simon started her career at SBI (Small Bone Innovation) where she worked for 23 years. After these successful years, she served as Director Finance & Administration for Olympus Biotech during 4 years where she managed the treasury, tax, controllership, internal audit and operations. Agnès has deep financial expertise and understanding of the healthcare sector. She than joined Histide to set-up and develop the Administration and Financials of the Company.
Histide™ has created an innovative platform of CRMs™-based complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins, healthy or diseased, and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.
In contrast to previously developed gene therapies or RNA based therapies, Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which may be irreversibly harmful to its functioning.
Recoding Therapeutics™ are instead an extracellular technological approach based on cell’s natural mechanisms of sensing and processing microenvironmental signals to adapt its fate accordingly. This allows for a precise and fine functional tuning that offers a master control over the cell biology.
Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration and healing of a large majority of the human body tissues.
As first applications, the CRMs™ were shown to regenerate more than twelve types of tissues and to heal several types of neoplastic diseases by recoding the tumor cells into healthy and physiologically functional cells.
Cell Recoding Molecules™ are therapeutic agents characterized by a molecular weight of less than 15,000 Daltons with the capacity to activate at least one growth factor receptor. They can be grafted or not to various microenvironmental mimics or devices. The first generation of CRMs developed by Histide are the Cell Recoding Peptides (CRPs).
Histide™ has a library of more than 14 000 CRPs™ developed on the basis of more than 25 “golden sequences” allowing specific non-covalent interactions with target cell receptors. A particular “golden sequence” has been established for directing each cell lineage. Histide’s CRP™ library is divided into 6 distinct classes based on their rational design.
Histide’s pipeline of investigational Recoding therapeutics is focused in 5 Strategic Therapeutic Areas :
Histide’s large & disruptive Technology Platform, protected by a strong & broad Patent Portfolio, will now explore the use of this innovative approach with the help of strong partners for each potential indication in pharmaceutical and other fields.
Histide is following a proven business model, teaming up with strong partners to maximize the potential of this impressive technology platform.